ANti-tick vaccines to prevent TIck-borne Diseases in Europe.
ANTIDotE is a consortium of 7 European research institutes funded by the European Commssion to investigate anti-tick vaccines. Our objective is to identify and characterize tick salivary gland proteins involved in tick feeding and tick-borne pathogen transmission, and to use this knowledge to develop and assess anti-tick vaccines to prevent multiple human tick-borne diseases.
The ANTIDotE consortium consists of 7 European participants, and an advisory board with 7 partners with different backgrounds and networks. This enables ANTIDotE to achieve its groundbreaking objectives.
For more information on the participants see the participants section of this website. The advisory board consists of Yale University (Yale), the Research Institite for Wildlife Health in Europe (Artemis), the Friedrich-Loeffler Institute (FLI), the National Institute of Public Health from the Czech Republic (NIPH CZ), Nationa Public Health Institute of Slovenia (NPHI SL), Center for Tick-borne Diseases in Hungary (CTB) and Theo Schetters (current protActivity and former Merck, Sharp & Dohme (MSD).
Annual meeting 25th – 26th of March 2015
We would like to announce that our 1st annual meeting was held in March in Český Krumlov, Czech Republic. The consortium was represented by each partner and their co-workers, also two advisors were invited to give external input, Theo Schetters (NL) and Erol Fikrig (USA).
Progress on the work packages was discussed in detail, as well as future plans. The meeting ended with a fruitful discussion.
The annual meeting was followed by a workshop organized by one of the ANTIDotE consortium partners, Petr Kopáček and was titled: Modbiolin workshop on Ticks & and Tick-Transmitted Diseases 2015. This workshop was attended by many of the ANTIDotE partners, who presented their preliminary data.